Sigachi Industries Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3a21x2wlo08jrq05gre4j4lc.pdf

Key Takeaways


Growth Engine: MCC Core & Capacity

Amit Raj Sinha: "the global MCC market is growing at a 5-year CAGR of 6.5%, Sigachi has delivered a 5-year CAGR of 26.47%, a testament of our differentiated capabilities and sharp execution."

API Turnaround: From Loss-Maker to Margin Driver


CCS: The Next Big Bet, With a Long Fuse

Amit Raj Sinha: "MCC acts as a binder, whereas a CCS acts as a disintegrant. So MCC puts the tablet together, whereas the CCS breaks up the tablet inside the body. So they are technically complementary and both of them have to be there in the drug."

O&M Services: The Quiet Scalability Story


Capital Allocation & Governance

Amit Raj Sinha: "We keep exploring options, but we don't really get into it until we understand the complete 5 forces model... we don't really jump in because the moment we jump in, somebody else is ready to take my position in the pharma industry, where my kind of leadership is already cemented."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGR>25% consolidated revenue growthNext 2-3 years
EBITDA marginSustain current levels and go beyond 25%Ongoing, no end date
MCC capacityExpand from 21,000 to 25,000 MTPA via debottleneckingOnce optimum utilization is reached
CCS plant commissioningBegin production at Dahej-2 SEZ facilityOctober 2026
CCS utilization ramp~35% in Year 1; full capacity within 2 years; 3-4x asset turnover in another 2 yearsFY27 through FY30
CCS capex spendINR40-50 croresFY26
O&M revenueDouble to ~INR75 croresFY26
API EBITDA marginTarget ~25%, possibly higherOngoing
API CEP filings5 additional filingsCalendar year 2025
API capacityAdd 150 KL (total 250 KL)Not specified
Segment growth floorAll segments (MCC, API, O&M, CCS) to grow at not less than 25% on averageOngoing
Per-kg value growth4-5% annual improvement expected to continueOngoing

Key Metrics

MetricQ4 FY25
Total operating income₹128 cr, +23.15% YoY
EBITDA₹28.5 cr, +74.84% YoY; margin 22.31%
Net profit₹16.2 cr, +7.28% YoY; PAT margin 12.63%
MCC segment revenue₹121.32 cr, +55.08% YoY
O&M segment revenue₹10.76 cr, +17.9% YoY
FY25 full-year operating income₹500 cr, +25.42% over FY24
FY25 full-year EBITDA₹112 cr, +46.21% YoY; margin 22.38%
FY25 full-year net profit₹70.5 cr, +23.25% YoY; PAT margin 14.09%
FY25 full-year MCC segment revenue₹409 cr, +35.75% from ₹302 cr in FY24
FY25 full-year O&M segment revenue₹41 cr, +17.66% YoY
FY25 full-year API segment revenue₹29 cr
Revenue growth outlook>25% CAGR over next 2–3 years
Sustainable EBITDA margin targetBeyond 25%
MCC current pricing₹214.3 per kg
MCC capacity utilization19,100 tons produced; capacity 21,000 MTPA, augmentable to 25,000 MTPA via debottlenecking
New 7,000 MTPA plant utilization68%, expected to scale near full capacity by FY26
CCS plant capex₹90 cr; commissioning expected October 2026
CCS asset turnover target3–4x over time
O&M segment FY26 revenue target~₹75 cr
API EBITDA margin~20% in FY25
API plant capacity utilization~35–40% on a full-year basis
Top 5 customer concentration43.98% of revenue
Top 10 customer concentration~60% of revenue
Total customer base~350 in FY25, may exceed 500 overall
CEP certifications4 filed, 1 secured for Metformin HCL; 5 more planned this calendar year
Forfeited preferential allotment amount₹25 cr, accounted under capital reserve